Quality of life considerations in psoriasis treatment.
Weiss, Stefan C, Kendra G Bergstrom, Sally A Weiss, and Alexa B Kimball. 2003. “Quality of Life Considerations in Psoriasis Treatment.”. Dermatology Nursing 15 (2): 120, 123-7; quiz 128.
Search
Search results
375 results found
Quantifying the harmful effect of psoriasis on health-related quality of life.
Weiss, Stefan C, Alexa B Kimball, David J Liewehr, Andrew Blauvelt, Maria L Turner, and Ezekiel J Emanuel. 2002. “Quantifying the Harmful Effect of Psoriasis on Health-Related Quality of Life.”. Journal of the American Academy of Dermatology 47 (4): 512-8.
Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis.
Kimball, Alexa Boer, and Ying Wu. 2009. “Cardiovascular Disease and Classic Cardiovascular Risk Factors in Patients With Psoriasis.”. International Journal of Dermatology 48 (11): 1147-56.
Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.
Gelfand, Joel M, Alexa B Kimball, Eliot N Mostow, Chiun-Fang Chiou, Vaishali Patel, Amy Xia, Bruce Freundlich, and Seth R Stevens. 2008. “Patient-Reported Outcomes and Health-Care Resource Utilization in Patients With Psoriasis Treated With Etanercept: Continuous versus Interrupted Treatment.”. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 11 (3): 400-7.
Risks of developing psychiatric disorders in pediatric patients with psoriasis.
Kimball, Alexa B, Eric Q Wu, Annie Guérin, Andrew P Yu, Magda Tsaneva, Shiraz R Gupta, Yanjun Bao, and Parvez M Mulani. 2012. “Risks of Developing Psychiatric Disorders in Pediatric Patients With Psoriasis.”. Journal of the American Academy of Dermatology 67 (4): 651-7.e1.
Skin carotenoid levels in adult patients with psoriasis.
Lima, X T, and A B Kimball. 2011. “Skin Carotenoid Levels in Adult Patients With Psoriasis.”. Journal of the European Academy of Dermatology and Venereology : JEADV 25 (8): 945-9.
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.
Gordon, K B, A B Kimball, D Chau, H N Viswanathan, J Li, D A Revicki, G Kricorian, and B G Ortmeier. 2014. “Impact of Brodalumab Treatment on Psoriasis Symptoms and Health-Related Quality of Life: Use of a Novel Patient-Reported Outcome Measure, the Psoriasis Symptom Inventory.”. The British Journal of Dermatology 170 (3): 705-15.
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
Kimball, A B, K A Papp, Y Wasfi, D Chan, R Bissonnette, H Sofen, N Yeilding, et al. 2013. “Long-Term Efficacy of Ustekinumab in Patients With Moderate-to-Severe Psoriasis Treated for up to 5 Years in the PHOENIX 1 Study.”. Journal of the European Academy of Dermatology and Venereology : JEADV 27 (12): 1535-45.
Current guidelines for psoriasis treatment: a work in progress.
Golbari, Nicole M, Martina L Porter, and Alexa B Kimball. 2018. “Current Guidelines for Psoriasis Treatment: A Work in Progress.”. Cutis 101 (3S): 10-12.
Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.
Kimball, Alexandra B, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Russel Burge, Chen-Yen Lin, and Gil Yosipovitch. 2018. “Long-Term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-Term Extension.”. Acta Dermato-Venereologica 98 (1): 98-102.